natgillin/translations-raw huggingface dataset:
A combination for use according to claim 3 or 4, wherein the β2 agonist is selected from the group comprising formoterol, salmeterol and QAB-149 optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija u skladu s patentnim zahtjevom 3, naznačena time, da je inhibitor PDE4 odabran iz skupine koju čine cilomilast, roflumilast, denbufilin i tetomilast, po izboru u obliku njihovih racemata, enantiomera, dijastereomera i mješavina navedenog te, po izboru, njihovih farmakološki kompatibilnih adicijskih soli kiselina.
A β2 agonist as defined in any one of claims 1 and 3 to 7, for simultaneous, concurrent, separate or sequential use in combination with an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the treatment of a respiratory disease as defined in claim 11 or 12, while producing less heart side-effects than a therapeutically equivalent combination of tiotropium with the β2 agonist. 
Uporaba (a) inhibitora PDE4 kako se definira u bilo kojem od patentnih zahtjeva 1 i 3 do 6, naznačena time, da se koristi za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijsku primjenu u kombinaciji s (b) antagonistom muskarinskih receptora M3 kako se definira u patentnom zahtjevu 1 ili 2 za liječenje bolesti dišnih putova kako se definira u patentnom zahtjevu 10 ili 11.
A polypeptide comprising an amino acid sequence that is at least 80% identical to SEQ ID NO: 1, wherein the amino acid sequence comprises an amino acid other than arginine substituted at the positions corresponding to position 48 and position 49 of SEQ ID NO:1, wherein the polypeptide, when dimerized, binds to a complex containing GFRalpha3 and RET, and wherein the polypeptide exhibits decreased heparin binding as compared to wild-type neublastin protein of SEQ ID NO:1. 
Polipeptid koji sadrži sekvencu aminokiselina koja je najmanje 80% identična aminokiselinama 15-113 u SEQ ID NO:1, naznačen time što sekvenca aminokiselina sadrži aminokiselinu različitu od arginina, supstituiranu na položajima koji odgovaraju položajima 48 i 49 u SEQ ID NO:1, pri čemu se polipeptid, kada je u obliku dimera, veže za kompleks koji sadrži GFRalpha3 i RET i pri čemu polipeptid ima smanjeno vezanje za heparin u usporedbi s proteinom neublastin divljeg tipa u SEQ ID NO:1.
The polypeptide of claim 1, wherein the arginine residue at position 48 and the arginine residue at position 49 of SEQ ID NO:1 are substituted with non-conservative amino acid residues. 
Polipeptid prema zahtjevu 1, naznačen time što su ostaci arginina na položajima 48 i 49 u SEQ ID NO:1 supstituirani nekonzervativnim ostacima aminokiselina.
The polypeptide of claim 1, wherein the arginine residue at position 48 and the arginine residue at position 49 of SEQ ID NO:1 are each substituted with glutamic acid. 
Polipeptid prema zahtjevu 1, naznačen time što su ostaci arginina na položajima 48 i 49 u SEQ ID NO:1 supstituirani glutaminskom kiselinom.
A process for the preparation of a pharmaceutical composition according to claim 1 comprising 
Postupak za izradu farmaceutskog pripravka u skladu sa zahtjevom 1, naznačen time, da sadrži
dissolving a binder in a solvent to produce a granulation liquid; 
otapanje veziva u otapalu da bi se pripremila tekućina za granulaciju;
optionally sieving the granulated pre-mix through a sieve with a mesh size of at least 1.0 mm; 
po izboru prosijavanje granulirane pre-smjese kroz sito otvora okna od najmanje 1.0 mm;
adding lubricant to the granulate for final blending. 
dodavanje lubrikanta u granulat za konačno miješanje.
preparing a coating suspension; 
pripremu suspenzije za oblaganje;
applying a primer anti-corrosive coat to the surface of the substrate; 
nanošenja temeljnog antikorozivnog premaza na površinu supstrata;
applying directly onto exposed primer coat(s) (a) from step (d) a fouling release system, preferably consisting of, 
nanošenja završnog premaza (topcoat) direktno na izloženi temeljni premaz ili više premaza (a) iz faze (d).
a silicone fouling release finish coat applied over and to the intermediate silicone tie-coat (e) (ii). 
silikonskog neobraštajućeg završnog premaza koji se nanosi preko silikonskog veznog međupremaza (e) (ii).
A method of coating a substrate according to claim 1, 2 or 3, wherein the antifouling coat (b) is capable of being washed off by low pressure water cleaning or high pressure water cleaning. 
Metoda premazivanja supstrata prema zahtjevima 1, 2 ili 3, gdje se provodi čišćenje antivegetativnog premaza (premaza protiv obraštanja) (b) ispiranjem vodom pod niskim ili visokim tlakom,.
A method of coating a substrate according to any preceding claim, wherein the total dry film thickness of the primer anti-corrosive coat (a) (i) is typically 30-500µm. 
Metoda premazivanja supstrata sukladno bilo kojem ranijem zahtjevu, naznačena time što ukupna debljina suhog filma temeljnog antikorozivnog premaza (a) (i) iznosi uobičajeno 30 - 500 μm.
A method of coating a substrate according to any preceding claim, wherein the total dry film thickness of the antifouling coat (b) immediately after application is 30-500µm. 
Metoda premazivanja supstrata sukladno bilo kojem ranijem zahtjevu, naznačena time što ukupna debljina suhog filma antivegetativnog premaza (b) odmah nakon aplikacije iznosi 30-500 μm.
applying directly onto exposed primer coat(s) (a) from step (d) a topcoat system. 
nanošenja završnog premaza (topcoat) direktno na izloženi temeljni premaz ili više premaza (a) iz faze (d).
A method of coating a substrate according to claim 1, wherein the topcoat system is a fouling release system, preferably consisting of, 
Metoda premazivanja supstrata sukladno zahtjevu 1, naznačena time, što je sustav završnog premaza neobraštajući premaz, a koji se po mogućnosti sastoji od
A method of coating a substrate according to any of claims 1, 3-9 or 11, wherein the topcoat system comprises a silyl acrylate based self polishing topcoat or an epoxy based topcoat. 
Metoda premazivanja supstrata sukladno bilo kojem od zahtjeva pod 1, 3do 9 ili 11, naznačena time što se sustav završnog premaza sastoji od samopolirajućeg završnog premaza na bazi silil akrilata ili završnog premaza na bazi epoksida.
p is 0, or 1 and when p is 0 then a direct bond is intended; 
p je 0, ili 1 i kada p je 0 tada je namjeravana direktna veza;
t is 0 or 1 and when t is 0 then a direct bond is intended; 
t je 0 ili 1 i kada t je 0 tada je namjeravana direktna veza;
is hydrogen, C1-6alkyl, heteroaryl, C3-7cycloalkyl, C1-6alkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; or C3-7cycloalkyl substituted with a substituent selected from hydroxy, amino, aryl and heteroaryl; 
je vodik, C1-6alkil, heteroaril, C3-7cikloalkil, C1-6alkil supstituiran sa supstituentom odabranim od hidroksi, amino, arila i heteroarila; ili C3-7cikloalkil supstituiran sa supstituentom odabranim od hidroksi, amino, arila i heteroarila;
A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 1 to 15. 
Farmaceutski pripravak naznačen time, da sadrži farmaceutski prihvatljiv nosač i kao aktivnu tvar terapeutski učinkovitu količinu spoja prema zahtjevu 1 do 15.
pancreatic carcinoma such as, for example exocrine pancreatic carcinoma), colon cancers (e.g. 
karcinoma gušterače, kao što su, primjerice egzokrini karcinomi gušterače), karcinoma crijeva (npr.
colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), oesophageal cancer, oral squamous carcinoma, tongue carcinoma, gastric carcinoma, nasopharyngeal cancer, hematopoietic tumours of lymphoid lineage (e.g. 
kolorektalnog karcinoma, kao što su, primjerice, adenokarcinomi debelog crijeva i adenomi debelog crijeva), raka jednjaka, oralnog planocelularnog karcinoma, karcinoma jezika, karcinoma želuca, karcinoma nazofarinksa, hematopoetskih tumora limfnih čvorova (npr.
acute lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), tumours of mesenchymal origin (e.g. 
akutne limfocitne leukemije, B-limfoma, Burkittovog limfoma), mijeloične leukemije (na primjer, akutne mijeloične leukemije (AML)), folikularnog karcinoma štitnjače, mijelodisplastičnog sindroma (MDS), tumora mezenkimalnog podrijetla (npr.
advanced breast cancer), kidney carcinoma, ovary carcinoma, cervical carcinoma, endometrial carcinoma, bladder carcinoma, prostate cancer including the advanced disease, testicular cancers, osteosarcoma, head and neck cancer and epidermal carcinoma. 
uznapredovanog raka dojke), karcinoma bubrega, karcinoma jajnika, karcinoma grlića maternice, endometrijskog karcinoma, karcinoma mjehura, raka prostate uključujući uznapredovale bolesti, karcinoma testisa, osteosarkoma, raka glave i vrata, epidermalnog karcinoma.
colorectal carcinomas, acute myelogenous leukaemia, ovary carcinoma, bladder carcinoma, prostate cancer, glioma. 
kolorektalnog karcinoma, akutne mijeloične leukemije, karcinoma jajnika, karcinoma mjehura, raka prostate, glioma.
reacting an intermediate of formula (II) with an intermediate of formula (III) wherein W is an appropriate leaving group such as, for example, halo, wherein the variables are as defined in claim 1; 
reakciju međuprodukta formule (II) sa međuproduktom formule (III) pri čemu W je prikladna odlazna skupina kao što je, na primjer, halo, [image] pri čemu su varijable kako je definirano u zahtjevu1;
reacting an appropriate carboxaldehyde of formula (IV), with an intermediate of formula (V), in the presence of an appropriate reagent, in a suitable solvent, wherein the variables are as defined in claim 1; 
reakciju odgovarajućeg karboksaldehida formule (IV), sa međuproduktom formule (V), u prisutnosti odgovarajućeg reakcijskog sredstva, u pogodnom otapalu, [image] pri čemu su varijable kako je definirano u zahtjevu1;
reacting an intermediate of formula (VII) with lithium aluminium hydride in a suitable solvent, with the formation of a compound of formula (I), wherein s is 1, herein referred to as compounds of formula (I-d). 
reakciju međuprodukta formule (VII) sa litij aluminij hidridom u pogodnom otapalu, uz stvaranje spoja formule (I), pri čemu s je 1, ovdje se nazivaju spojevi formule (I-d).
A and D are independently selected from hydrogen, halogen, nitrile, C1-3 alkyl, C1-3 alkoxy, wherein the latter 2 groups can be optionally substituted by one or more halogen atoms; 
[image] naznačen time da: A i D su nezavisno izabrani iz vodika, halogena, nitrila, C1-3 alkila, C1-3 alkoksi, pri čemu zadnje 2 skupine mogu opcijski biti supstituirane sa jednim ili više atoma halogena;
A compound according to claim 1 or 2 in which the group SO2-Y-Z is at the 4-position of the phenyl ring. 
Spoj prema zahtjevu 1 ili 2, naznačen time, da se u njemu skupina SO2-Y-Z nalazi na poziciji 4 u fenilnom prstenu.
A compound according to claim 1 or 2 in which the group SO2-Y-Z is at the 4-position of the phenyl ring, ortho to both group A and group D. 
Spoj prema zahtjevu 1 ili 2, naznačen time, da se u njemu skupina SO2-Y-Z nalazi na poziciji 4 u fenilnom prstenu, orto u odnosu na obje skupine A i D.
A compound according to claim 1 or 2 in which the group SO2-Y-Z is at the 4-position of the phenyl ring, ortho to the group A and meta to the group D. 
Spoj prema zahtjevu 1 ili 2, naznačen time, da se u njemu skupina SO2-Y-Z nalazi na poziciji 4 u fenilnom prstenu, orto u odnosu na skupinu A i meta u odnosu na skupinu D.
A compound of formula (II): wherein R1, R2, A, D, X, Y and Z are as defined in claim 1 and R4 is a C1-10 alkyl group. 
Spoj, naznačen time, da ima formulu (II): [image] pri čemu R1, R2, A, D, X, Y i Z su definirani kao u zahtjevu 1, a R4 je C1-10 alkilna skupina.
in a first step, one or more aliquots of the compound of formula (III) and of the base are added to an aqueous solution of the compound of formula (II), in a simultaneous, consecutive or alternated way of addition, at a temperature ranging from 10°C to 30°C; and 
u prvom koraku, jedan ili više alikvota spoja formule (III) i baze se dodaju u vodenu otopinu spoja formule (II), u istovremenom, uzastopnom ili naizmjeničnom načinu dodavanja, pri temperaturi u rasponu od 10°C do 30°C; i
in a second step, the reaction mixture is warmed up to a temperature ranging from 30°C to 60°C and, optionally, one or more aliquots of the compound of formula (III) and of the base are added to the reaction mixture, in a simultaneous, consecutive or alternated way of addition, up to completion of the reaction. 
u drugom koraku, reakcijska mješavina se zagrijava do temperature u rasponu od 30°C do 60°C i, po izboru, jedan ili više alikvota spoja formule (III) i baze se dodaju u reakcijsku mješavinu, u istovremenom, uzastopnom ili naizmjeničnom načinu dodavanja, sve do završetka reakcije.
A process according to claim 1 wherein X, within the compound of formula (III), is a chlorine or bromine atom. 
Postupak prema zahtjevu 1 naznačen time da X, unutar spoja formule (III), je atom klora ili broma.
A process according to claim 2 wherein the compound of formula (III) is bromoacetic acid. 
Postupak prema zahtjevu 2 naznačen time da spoj formule (III) je bromooctena kiselina.
A process according to claim 1 wherein the base is selected from the group consisting of alkaline or alkaline-earth metals hydroxides. 
Postupak prema zahtjevu 1 naznačen time da je baza odabrana iz skupine koja se sastoji od metalnih hidroksida alkalnih ili zemnoalkalnih metala.
A process according to claim 1 wherein the compound of formula (II) is obtained by alkylating diethylentriamine with 2-chloro-3-(phenylmethoxy)propionic acid potassium salt. 
Postupak prema zahtjevu 1 naznačen time da je spoj formule (II) dobiven alkilacijom dietilentriamina sa 2-kloro-3-(fenilmetoksi)propionska kiselina kalijevom soli.
A process according to claim 8 wherein, in step (a), from 3 to 8 aliquots of compound of formula (III) and from 3 to 8 aliquots of base are added to an aqueous solution of the compound of formula (II), in a simultaneous, consecutive or alternated way of addition. 
Postupak prema zahtjevu 8 naznačen time da, u koraku (a), od 3 do 8 alikvota spoja formule (III) i od 3 do 8 alikvota baze se dodaje u vodenu otopinu spoja formule (II), u istovremenom, uzastopnom ili naizmjeničnom načinu dodavanja.
A process according to claim 10 wherein, in step (b), from 1 to 8 aliquots of compound of formula (III) and from 1 to 8 aliquots of base are added to the reaction mixture, in a simultaneous, consecutive or alternated way of addition. 
Postupak prema zahtjevu 10 naznačen time da, u koraku (b), od 1 do 8 alikvota spoja formule (III) i od 1 do 8 alikvota baze se dodaje u reakcijsku mješavinu, u istovremenom, uzastopnom ili naizmjeničnom načinu dodavanja.
An adhesive patch for the transdermal administration of a compound of formula (I): in which R1; R2, R3 and R4 are the same as or different from each other and each represents an oxo group, a hydroxy group, a mercapto group, a hydrogen atom, a halogen atom, an alkoxy group or an aryloxy group; and the dotted line indicates that there may be a single or double bond between one of the respective pairs of carbon atoms or an ester thereof, said patch comprising a substrate and a layer of adhesive on the substrate, in which said adhesive comprises a copolymer of from 40 to 60% by weight of methoxyethyl acrylate, from 30 to 40% by weight of lauryl acrylate or methacrylate and from 10 to 25% by weight of a polar monomer, said adhesive having dispersed therein at least one compound of formula (I) or an ester thereof. 
Adhezivni flaster, naznačen time što je namijenjen za transdermalnu primjenu spoja formule (I): [image] u kojoj R1, R2, R3 i R4 su međusobno isti ili različiti, a svaki od njih predstavlja okso skupinu, hidroksi skupinu, merkapto skupinu, atom vodika, atom halogena, alkoksi skupinu ili ariloksi skupinu; gdje iscrtkana linija označuje da tu može biti jednostruka ili dvostruka veza između jednog od odgovarajućih parova atoma ugljika ili odgovarajućeg estera, gdje navedeni flaster sadrži supstrat i sloj ljepila na supstratu, gdje navedeno ljepilo sadržo kopolimer od 40 do 60 %, težinski, metoksietil-akrilata, 30 do 40 %, težinski, lauril-akrilata ili metakrilata i 10 do 25 %, težinski, polarnog monomera, a u navedenom ljepilu je dispergiran najmanje jedan spoj formule (I) ili njegov ester.
A patch according to any one of Claims 1 to 7, in which the amount of units derived from methoxyethyl acrylate in the copolymer is from 45 to 55% by weight. 
Flaster u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što sadrži količinu jedinica dobivenih iz metoksietil-akrilata u kopolimeru koja iznosi 45 do 55, težinski.
A patch according to Claim 10, in which the polar monomer is N-vinyl-2-pyrrolidone. 
Flaster u skladu s patentnim zahtjevom 10, naznačen time što polarni monomer je N-vinil-2-pirolidon.
A patch according to any one of Claims 1 to 15, for use in the treatment or prevention by transdermal application of osteoporosis, osteogenesis, neuronal cell death, or ischaemia-induced damage to peripheral organs. 
Flaster u skladu s bilo kojim od patentnih zahtjeva 1 do 15, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju, transdermalnom primjenom, osteoporoze, osteogeneze, smrti živčanih stanica ili oštećenja perifernih organa uzrokovanog ishemijom.
An adhesive composition according to Claim 17, for use in the treatment or prevention by transdermal application of osteoporosis, osteogenesis, neuronal cell death, or ischaemia-induced damage to peripheral organs. 
Adhezivni pripravak u skladu s patentnim zahtjevom 17, naznačen time što je namijenjen upotrebi u liječenju ili sprječavanju, transdermalnom primjenom, osteoporoze, osteogeneze, smrti živčanih stanica ili oštećenja perifernih organa uzrokovanog ishemijom.
The use according to claim 1 or 2, wherein said vector further comprises one or more DNA sequences coding for regulatory elements selected from 5'UTRs, introns, 3'UTRs, mRNA 3' end processing sequences, polyadenylation sites, and internal ribosome entry sequences (IRES). 
Upotreba prema zahtjevu 1 ili 2, naznačena time da navedeni vektor nadalje sadrži jednu ili više DNA sekvenci kodiranja za regulatorne elemente koji se biraju iz 5'UTR, introna, 3'UTR, mRNA 3' završne obrade sekvence, poliadenilacijskog mjesta, i unutarnjih ribosomskih ulaznih sekvenci (IRES).
The use according to any of claims 1 to 4, wherein said vector further comprises one or more DNA elements selected from boundary elements, locus control regions (LCRs), matrix attachment regions (MARs), and elements for recombination and cassette exchange. 
Upotreba prema bilo kojem od zahtjeva 1 do 4, naznačena time da navedeni vektor nadalje sadrži jedan ili više DNA elemenata odabranih od graničnih elemenata, lokus kontrolnih područja (LCR), matričnih vezanih regija (MAR), i elemenata za rekombinaciju i kasetnu izmjenu.
The use according to any of claims 1 to 6, wherein the polypeptide of interest is selected from EPO, G-CSF, GM-CSF, a chain of a humanized antibody, a cytokine, a coagulation factor, etanercept, tPA, an integrin or muteins, fragments, functional derivatives, fusion proteins thereof. 
Upotreba prema bilo kojem od zahtjeva 1 do 6. naznačena time da je polipeptid od interesa odabran od EPO, G-CSF, GM-CSF, lanca humaniziranih antitijela, citokina, koagulacijskog faktora, etanercepta, tPA, integrina ili muteina, fragmenata, funkcionalnih derivata, te njegovih fuzijskih proteina.
A process for the production of a polypeptide of interest comprising the step of culturing a CHO cell according to claim 20. 
Postupak za dobivanje polipeptida od interesa naznačen time da sadrži korak uzgoja CHO stanica prema zahtjevu 20.
R5' and R5" are independently selected from hydrogen and C1-3alkyl optionally substituted by 1, 2 or 3 substituents independently selected from hydroxyl, halo, C1-3alkoxy, carboxy and cyano or R5' and R5" together with the nitrogen atom to which they are attached form a 4-7 membered saturated ring)] and optional substituents for heterocyclyl and the heterocyclyl group in heterocyclylC1-3alkyl are additionally selected from R21, R21CO- R21S(O)k (wherein k is 0, 1 or 2) and R21CH2OC(O)- wherein R21 is phenyl optionally substituted by 1 or 2 substituents independently selected from halo, hydroxy, cyano and trifluoromethyl; or when Q is a bond R1 may also be hydrogen, wherein heterocyclyl is a 4-7 saturated, monocyclic ring having 1-3 ring heteroatoms selected from nitrogen, oxygen and sulphur; 
' i R5" su nezavisno odabrani od vodika i C1-3alkila opcionalno supstituirani sa 1, 2 ili 3 supstituenta nezavisno odabranih od hidroksil, halo, C1-3alkoksi, karboksi i cijano ili R5' i R5" zajedno sa atomom dušika na koji su spojeni tvore 4-7 člani zasićeni prsten)] i opcijskih supstituenata za heterociklil i heterociklilna skupina u heterociklilC1-3alkilu su dodatno odabrani od R21, R21CO- R21S(O)k (pri čemu k je 0, 1 ili 2) i R21CH2OC(O)- pri čemu R21 je fenil opcionalno supstituiran sa 1 ili 2 supstituenta nezavisno odabranih od halo, hidroksi, cijano i trifluorometil; ili kada Q je veza R1 može također biti vodik, pri čemu heterociklil je 4-7 zasićeni, monociklički prsten koji ima 1-3 heteroatoma prstena odabrana od dušika, kisika i sumpora;
is selected from C3-7cycloalkyl(CH2)m-, and C6-12polycycloalkyl(CH2)m- (wherein the cycloalkyl and polycycloalkyl rings optionally contain 1 or 2 ring atoms independently selected from nitrogen, oxygen and sulphur; m is 0, 1 or 2 and the rings are optionally substituted by 1, 2 or 3 substituents independently selected from R6); 
je odabran od C3-7cikloalkil(CH2)m-, i C6-12policikloalkil(CH2)m- (pri čemu prsteni cikloalkila i policikloalkila opcijski sadrže 1 ili 2 atoma prstena nezavisno odabranih od dušika, kisika i sumpora; m je 0, 1 ili 2 i prsteni su opcionalno supstituirani sa 1, 2 ili 3 supstituenta nezavisno odabranih od R6);
and R3 together with the nitrogen atom to which they are attached form a saturated mono, bicyclic or bridged ring system optionally containing 1 or 2 additional ring heteroatoms selected from nitrogen, oxygen and sulphur and which is optionally fused to a saturated, partially saturated or unsaturated monocyclic ring wherein the resulting ring system is optionally substituted by 1, 2, or 3 substituents independently selected from R7; 
i R3 zajedno sa atomom dušika na koji su spojeni tvore zasićeni mono, biciklički ili premošteni sustav prstena koji opcijski sadrži 1 ili 2 dodatna heteroatoma prstena odabranih od dušika, kisika i sumpora i koji su opcijski spojeni na zasićeni, djelomično zasićeni ili nezasićeni monociklički prsten pri čemu je sustav rezultirajućeg prstena opcionalno supstituiran sa 1, 2, ili 3 supstituenta nezavisno odabranih od R7;
A process according to claim 7, wherein the crystallization solvent is a simple solvent of isopropyl alcohol or s-butyl alcohol, or a mixed solvent of s-butyl alcohol and water or a mixed solvent of isopropyl alcohol and water. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da je kristalizacijsko otapalo jednostavno otapalo od izopropil alkohola ili s-butil alkohola, ili miješano otapalo s-butil alkohola i vode ili miješano otapalo izopropil alkohola i vode.
A process according to claim 7, wherein the crystallization solvent is a mixed solvent of s-butyl alcohol and water (volume ratio = 3:1-5:1) or a mixed solvent of isopropyl alcohol and water (volume ratio = 9:1-10:1). 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da je kristalizacijsko otapalo miješano otapalo s-butil alkohola i vode (omjer volumena = 3:1-5:1) ili miješano otapalo izopropil alkohola i vode (omjer volumena = 9:1-10:1).
A process according to claim 7, wherein the crystallization solvent is a mixed solvent of s-butyl alcohol and water (volume ratio = 3.9:1-4.1:1). 
Postupak u skladu s patentnim zahtjevom 7, naznačen time, da je kristalizacijsko otapalo miješano otapalo s-butil alkohola i vode (omjer volumena = 3.9:1-4.1:1).